Login / Signup

Near fatal case of mirvetuximab soravtansine-gynx induced interstitial lung disease and a review of the primary literature.

Joshua ClarkAndrew BlakeScott VasherRichard C BoucherAlexis R JonesHee Jae ChoiBenjamin B Albright
Published in: Gynecologic oncology reports (2024)
•Mirvetuximab soravtansine-gynx should be recognized as a cause of drug-induced interstitial lung disease (ILD).•Radiographic manifestations of mirvetuximab soravtansine-gyn induced ILD include organizing pneumonia pattern.•Interstitial lung disease related to mirvetuximab soravtansine-gyn can cause high morbidity.•Corticosteroids are commonly used in drug-induced interstitial lung disease and should be considered when encountering ILD related to mirvetuximab.•Changes to manufacturer dosing guidelines for grade 1 pneumonitis related to mirvetuximab soravtansine-gyn need to be considered.
Keyphrases